SpyGlass Pharma Finishes Phase I/II Enrollment for Long-Term Glaucoma Drug Delivery Study

SpyGlass is gearing up for a significant milestone with the FDA as it seeks to progress its Drug Delivery Platform into pivotal Phase III studies. This innovative platform shows promise in enabling cataract surgeons to treat glaucoma during routine cataract surgeries.

Based in Aliso Viejo, California, SpyGlass Pharma has recently announced the completion of patient enrollment in its Phase I/II clinical trial. This randomized, multi-center, controlled trial (NCT06120842) is assessing the platform’s effectiveness in patients suffering from glaucoma or ocular hypertension. Designed to release bimatoprost over several years, the SpyGlass platform aims to reduce intraocular pressure (IOP) and is implanted during standard cataract operations.

Patrick Mooney, the CEO of SpyGlass Pharma, emphasized the importance of this milestone. He highlighted the company’s dedication to improving life quality for individuals with chronic eye conditions, such as glaucoma, which can result in vision loss. Mooney expressed optimism about the ongoing collaboration with the FDA as the company strives to advance towards large-scale Phase III trials.

SpyGlass Pharma’s co-founder, Dr. Malik Kahook, also highlighted the platform’s potential impact. He noted that the technology could significantly enhance glaucoma treatment during routine cataract surgeries due to its compatibility with standard surgical methods. This compatibility could lead to widespread adoption among surgeons and practices, differentiating the SpyGlass platform from other existing glaucoma treatments.

Dr. Kahook expressed gratitude to the investigators and patients participating in the clinical trial, acknowledging their crucial role in advancing the study. He believes their involvement brings the company closer to offering a treatment that could markedly improve care for glaucoma patients globally.

SpyGlass Pharma’s Drug Delivery Platform, equipped with bimatoprost, is designed to provide targeted tissues with up to three years of the drug. The company plans to continue sharing data from the initial human study, which recently published 18-month findings, and from the ongoing Phase I/II trial as results become available. SpyGlass aims to collaborate closely with the U.S. Food and Drug Administration (FDA) to move the program towards commercial approval.

SpyGlass Pharma was co-founded by Dr. Malik Y. Kahook and Glenn Sussman. The company is dedicated to developing the first-ever, intraocular lens (IOL)-mounted, controlled release drug delivery platform capable of administering multiple years of therapy. SpyGlass has garnered support from prominent investors including New Enterprise Associates (NEA), RA Capital, Vensana Capital, Samsara BioCapital, and Vertex Ventures HC. The technology was initially developed at the Sue Anschutz-Rodgers Eye Center of the University of Colorado School of Medicine and later spun off after securing Series A funding.

This progress marks a significant step in the development of a treatment that could transform the management of glaucoma during routine cataract surgeries, offering hope to millions of patients worldwide.